SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

14 11月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

07 11月 2024 16:05:01 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

29 10月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

16 10月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

02 10月 2024 16:30:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming September Investor Conferences

04 9月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

05 8月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

29 7月 2024 16:05:16 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 7月 2024 13:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 6月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

16 5月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

15 5月 2024 16:05:37 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

08 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 5月 2024 16:07:35 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

13 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

06 3月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

28 2月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

26 2月 2024 08:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 1月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Spero Therapeutics Provides Corporate Update and 2024 Outlook

05 1月 2024 08:05:00 条件 Nasdaq GlobeNewswire